Estimation of oxidative stress markers in chronic kidney disease

Kidney and Blood Pressure Research

Volumn 34, Issue 1, 2011, Pages 12-19

  Kuchta, Agnieszka ^a   Pacanis, Anastasis ^a   Kortas Stempak, Barbara ^a   Ćwiklińska, Agnieszka ^a   Ziȩtkiewicz, Marcin ^a   Renke, Marcin ^a   Rutkowski, Boleslaw ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Chronic kidney disease; Oxidized low density lipoprotein; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BIOCHEMICAL MARKER; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; UREMIA;

ADULT; AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; UREMIA;

EID: 78149311165     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321508     Document Type: Article

References (40)

1. Tylicki L, Rutkowski B, Horl WH: Antioxidants: a possible role in kidney protection. Kidney Blood Press Res 2003; 26: 303-314.
2. Araujo M, Welch WJ: Oxidative stress and nitric oxide in kidney function. Curr Opin Nephrol Hypertens 2006; 15: 72-77.
3. Przekwas M, Malgorzewicz S, Zdrojewski Z, et al.: Influence of predialysis oxidative stress on peroxidation processes after renal transplantation. Transplant Proc 2003; 35: 2170-2173.
4. Vaziri ND: Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 93-99.
5. Rutkowski P, Malgorzewicz S, Slominska E, et al.: Interrelationship between uremic toxicity and oxidative stress. J Ren Nutr 2006; 16: 190-193.
6. Kitiyakara C, Gonin J, Massy Z, Wilcox CS: Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidate stress and hyperhomocysteinemia. Curr Opin Nephrol Hypertens 2000; 9: 477-487.
7. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
8. Oberg BP, McMenamin E, Lucas FL, et al.: Increased prevalence of oxidant stress and inflammation in patients with moDerate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016.
9. Himmelfarb J, Lazarus JM, Hakim R: Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991; 17: 271-276.
10. Ward RA, McLeish KR: Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 2003; 27: 230-236.
11. Samouilidou EC, Grapsa EJ, Kakavas I, et al.: Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int Urol Nephrol 2003; 35: 393-397.
12. Ceballos-Picot I, Witko-Sarsat V, Merad- Boudia M, et al.: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996; 21: 845-853.
13. Ozden M, Maral H, Akaydin D, et al.: Erythrocyte glutathione peroxidase activity, plasma malondialdehyde and erythrocyte glutathione levels in hemodialysis and CAPD patients. Clin Biochem 2002; 35: 269-273.
14. Getz GS, Reardon CA: Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 2004; 15: 261-267.
15. Wang Y, Fang X, Wang S, et al.: Relation between plasma oxLDL antibodies and oxLDL in the circulation. Inflammation 2007; 30: 7-13.
16. Kaneda H, Taguchi J, Ogasawara K, et al.: Increased level of adVanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002; 162: 221-225.
17. Wilson DW, Metz HN, Graver LM, Rao PS: Direct method for quantification of free malondialdehyde with high-performance capillary electrophoresis in biological samples. Clin Chem 1997; 43: 1982-1984.
18. AnDerstam B, Ann-Christin BH, Valli A, et al.: Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. Clin Chim Acta 2008; 393: 114-118.
19. MacKness B, Mackness MI, Durrington PN, et al.: Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 2000; 30: 4-10.
20. Zachara BA, Wlodarczyk Z, Andruszkiewicz J, et al.: Glutathione and glutathione peroxidase activities in blood of patients in early stages following kidney transplantation. Ren Fail 2005; 27: 751-755.
21. Zachara BA, Salak A, Koterska D, et al.: Selenium and glutathione peroxidases in blood of patients with different stages of chronic renal failure. J Trace Elem Med Biol 2004; 17: 291-299.
22. Avissar N, Ornt DB, Yagil Y, et al.: Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol 1994; 266:C367-C375.
23. Zachara BA, Trafikowska U, Adamowicz A, et al.: Selenium, glutathione peroxidases, and some other antioxidant parameters in blood of patients with chronic renal failure. J Trace Elem Med Biol 12001; 5: 161-166.
24. Sutherland WH, de Jong SA, Walker RJ: Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study. Nephrol Dial Transplant 2004; 19: 75-82.
25. Schiavon R, Battaglia P, De Fanti E, et al.: HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002; 324: 39-44.
26. Schiavon R, De Fanti E, Giavarina D, et al.: Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996; 247: 71-80.
27. Palleschi S, De Angelis S, Diana L, et al.: Reliability of oxidative stress biomarkers in hemodialysis patients: a comparative study. Clin Chem Lab Med 2007; 45: 1211-1218.
28. Boaz M, Matas Z, Biro A, et al.: Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1078-1083.
29. Yoshimura S, Suemizu H, Nomoto Y, et al.: Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron 1996; 73: 207-211.
30. Holvoet P, Harris TB, Tracy RP, et al.: Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elDerly: findings from the Health, Aging, and Body Composition Study. Arterioscler Thromb Vasc Biol 2003; 23: 1444-1448.
31. Takenaka T, Takahashi K, Kobayashi T, et al.: Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients. Clin Nephrol 2002; 58: 33-37.
32. Diepeveen SH, Verhoeven GH, Van Der Palen J, et al.: Oxidative stress in patients with endstage renal disease prior to the start of renal replacement therapy. Nephron Clin Pract 2004; 98:c3-c7.
33. Liu SX, Hou FF, Guo ZJ, et al.: AdVanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 1156-1162.
34. Witko-Sarsat V, FriedlanDer M, Nguyen Khoa T, et al.: AdVanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
35. Witko-Sarsat V, FriedlanDer M, Capeillere-Blandin C, et al.: AdVanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
36. Capeillere-Blandin C, Gausson V, Nguyen AT, et al.: Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Transplant 2006; 21: 1555-1563.
37. Boulanger E, Moranne O, Wautier MP, et al.: Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study. Perit Dial Int 2006; 26: 207-212.
38. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radicalcaused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858-6862.
39. Verdecchia P, Schillaci G, Reboldi G, et al.: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072-1078.
40. Capasso G, Jaeger P, Robertson WG, Unwin RJ: Uric acid and the kidney: urate transport, stone disease and progressive renal failure. Curr Pharm Des 2005; 11: 4153-4159.